Abstract

Actinic keratosis (AK) affects millions of people worldwide, and its prevalence continues to increase. AK lesions are caused by chronic ultraviolet radiation exposure, and the presence of two or more AK lesions along with photodamage should raise the consideration of a diagnosis of field cancerization. Effective treatment of individual lesions as well as field cancerization is essential for good long-term outcomes. The Swiss Registry of Actinic Keratosis Treatment (REAKT) Working Group has developed clinical practice guidelines for the treatment of field cancerization in patients who present with AK. These guidelines are intended to serve as a resource for physicians as to the most appropriate treatment and management of AK and field cancerization based on current evidence and the combined practical experience of the authors. Treatment of AK and field cancerization should be driven by consideration of relevant patient, disease, and treatment factors, and appropriate treatment decisions will differ from patient to patient. Prevention measures and screening recommendations are discussed, and special considerations related to management of immunocompromised patients are provided.

Highlights

  • Actinic keratoses (AKs) are caused by chronic ultraviolet (UV) radiation exposure

  • AK lesions are caused by chronic ultraviolet radiation exposure, and the presence of two or more AK lesions along with photodamage should raise the consideration of a diagnosis of field cancerization

  • The Swiss Registry of Actinic Keratosis Treatment (REAKT) Working Group has developed clinical practice guidelines for the treatment of field cancerization in patients who present with AK

Read more

Summary

Swiss clinical practice guidelines on field cancerization of the skin

Günther Hofbauera, Mark Anlikerb, Wolf-Henning Boehnckec, Christoph Brandd, Ralph Brauna, Olivier Gaidee, Jürg Hafnera, Robert Hungerf, Peter Iting, Gina Kaeuperh, Stephan Lautenschlageri, Carlo Mainettij, Markus Streitk a Dermatologische Klinik, UniversitätsSpital Zürich, Switzerland;b Klinik für Dermatologie/Allergologie, Kantonsspital St. Gallen, Switzerland;c Service de Dermatologie et Vénéréologie, Hôpitaux Universitaires de Genève, Switzerland; d Dermatologische Abteilung, Kantonsspital Luzern, Switzerland; e Service de Dermatologie et Vénéreologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; f Universitätsklinik für Dermatologie, Inselspital Bern, Switzerland; g Dermatologie, Universitätsspital Basel, Basel, Switzerland; h Knoxville, Tennessee, USA; i Dermatologisches Ambulatorium, Stadtspital Triemli, Zürich, Switzerland; j Dermatologia, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland; k Dermatologie/Allergologie, Kantonsspital Aarau, Switzerland

Summary
Introduction
Review article
About these guidelines
Actinic keratosis and field cancerization background
AK progression to SCC
Epidemiology and risk factors
Actinic keratosis and field cancerization management
Treatment considerations
Recalcitrant lesion requires biopsy by dermatologist
Treatment options
LD and FD
Excision Skin grafting Chemical peels Laser
Findings
Management considerations for the immunocompromised
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call